Prasugrelmedieret hæmning af trombocytaggregering viser lav varians imellem forsøgspersonerne (12%) og hos forsøgspersonerne (9%) med både 5 µM og 20 µM ADP.
Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject (12%) and within-subject (9%) variability with both 5 µM and 20 µM ADP.